[Featured Stock] Boryung Rises on Possibility of Distributing Lilly's Obesity Treatment 'Mounjaro'

Boryung is showing strength. With the domestic launch of Novo Nordisk's obesity treatment drug 'Wegovy' confirmed, it is interpreted that buying interest is gathering on the possibility of Boryung being selected as the domestic distributor for another obesity treatment drug, Eli Lilly's Mounjaro (Tirzepatide).

As of 10:21 AM on the 8th, Boryung was trading at 11,280 KRW, up 680 KRW (6.42%) compared to the previous trading day.

According to related industry sources, Korea Novo Nordisk Pharmaceutical will sell Wegovy domestically in mid-month. Julipharm Korea, which handles the intermediate distribution of Wegovy, will start accepting orders for Wegovy stock through its online site from the 15th of this month.

As the sales of Wegovy begin in earnest, interest in other obesity treatments is also increasing. Eli Lilly's Mounjaro received approval as an adjunct for chronic weight management about a year after its approval as a type 2 diabetes treatment in June last year.

Boryung is being mentioned as a candidate for the distributor of Mounjaro. Since it has a product sales contract and handles distribution for Lilly's diabetes treatment Trulicity, it is predicted that there will be an advantage in distributing Mounjaro, a similar drug.

In August this year, Stunning Value Research also mentioned the possibility of Boryung distributing Mounjaro. Researcher Namgung Jun said, "Mounjaro is a once-weekly subcutaneous injection (SC) used as an adjunct to a low-calorie diet and exercise regimen for chronic weight management in adult patients," and added, "Boryung acquired domestic rights from Eli Lilly for ‘Zyprexa’, ‘Alimta’, and ‘Gemzar’, and is co-marketing the diabetes treatment ‘Trulicity’."

He continued, "Due to this ongoing business relationship with Eli Lilly, co-marketing of ‘Mounjaro’, a drug similar to ‘Trulicity’, is expected."

This content was produced with the assistance of AI translation services.